Osimertinib/EGFR (UniProt P00533) - Comprehensive Analysis
This report summarizes Convexia’s Science Agent analysis of Osimertinib (EGFR). Results are derived from 30+ models across binding, PK, safety, and mechanistic simulation. Full execution required multiple hours of high-performance GPU compute.